Rodu’s research focuses on the substitution of safer tobacco products by smokers who are unable or unwilling to quit smoking with conventional cessation methods because of their addiction to nicotine. His research in comparative epidemiology established the scientific foundation for harm reduction and he continues to study clinical and social interventions aimed at harm reduction.
Latest posts by Brad Rodu (see all)
- UC San Francisco Authors Inadvertently Validate Our Call for Retraction - April 6, 2018
- Retract the UC San Francisco E-Cigarette “Gateway” Study - April 6, 2018
- FDA’s New Vision for Tobacco Harm Reduction - August 1, 2017
A commentary on “the political, social, genetic, and neuroscientific challenges in continuing an abstinence-only approach to nicotine use” was recently published by University of Ottawa Faculty of Law Adjunct Professsor David Sweanor and student Adam Houston.
In their Ottawa Law Review article (here), Sweanor and Houston observe that the “health catastrophe” of smoking “results not from the nicotine that smokers seek, but from the inhalation of smoke in order to obtain it” They note that “non-combustion tobacco products — medicinal nicotine, various types of smokeless tobacco products, and now vapour products …effectively deliver nicotine without the inhalation of smoke,” and they believe that “shifting the market to non-combustion alternatives not only has the potential to achieve a public health breakthrough of truly historic significance, but is also a rather simple idea.”
According to Sweanor and Houston, “tobacco control policies hostage to an abstinence-only agenda” is so destructive “that even major US governmental health bodies avoid telling the public of the huge differential in risk between smokeless tobacco and cigarettes.” I have repeatedly described the how the CDC doesn’t acknowledge the minimal risks of smokeless tobacco (here andhere).
My decades-long effort to educate American tobacco consumers has been met with relentless opposition from anti-tobacco forces. Sweanor and Houston show that wrong-headed opposition by health professionals is not unique to tobacco harm reduction.
Vaccines have been challenged for over 200 years. “Dr. Edward Jenner is rightly honoured for the simple idea that cowpox [vaccination] could protect against smallpox, but his breakthrough in understanding the importance of vaccinations faced opposition…from those who saw such things as interfering with the will of God… As a result, widespread immunization took many decades to achieve.”
Physicians rejected hand-washing. “The ground-breaking work of Dr. Ignác Semmelweis, on the simple idea of doctors washing their hands between conducting autopsies and attending to childbirth, was not merely ignored for decades, but his sanitary procedures were actually abandoned on the orders of his superiors, who did so after his measures had proven exceedingly effective at preventing an epidemic of unnecessary maternal and child deaths.” (emphasis in original)
Sweanor and Houston call for “intelligent regulatory oversight,” but it’s an oxymoron in the U.S. today, as evidenced by recent FDA actions on smokeless tobacco. The FDA has conducted a misinformation campaign on cancer risks (here) that includes the conflation of “tobacco” with “smoking” (here). Now, according to a report in The Hill (here), the FDA wants to lower the level of one or more tobacco-specific nitrosamines (TSNAs) in smokeless products.
As I documented six years ago (here), TSNAs “are present [in tobacco products] in vanishingly small concentrations – mainly in the single-digit parts-per-million range… Despite decades of epidemiologic research, long-term use of Swedish or American smokeless tobacco products (other than dry powdered snuff) has not been associated in a significant way with ANY disease.”
I predicted that “anti-tobacco extremists will call for reductions. However, since there is virtually no evidence that current TSNA levels are associated with ANY measurable cancer risks, it is inconceivable that a reduction in levels will produce any measurable benefit.”
The Hill reports that the Campaign for Tobacco-Free Kids is taking credit for the FDA proposal. CTFK’s Denis Henigan said, “We wrote to the agency and said well look if these products have such lower levels than clearly it’s feasible to manufacture products with lower levels of carcinogens and you should draft a product standard. It appears FDA has proposed to do something like that, something we asked for or close to it.”
It is wrong for CTFK to drive FDA action in the absence of any scientific rationale relate
d to risk reduction, when current risks are near zero.
[First published at Tobacco Truth at http://rodutobaccotruth.blogspot.com/]